The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors (NNRs), to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). The present invention includes compounds which bind with high affinity to NNRs of either the α4β2 subtype, or the α6-containing subtype, or both NNR subtypes. Formula (I), wherein: each m is identical and is 0 or 1； each n is identical and is 0 or 1； when each m is 0, then each n is 1； when each m is 1, then each n is 0； Ris -C(O)-R, -C(O)O-R, -C(O)NH-R, -C(O)-(CH)-X-R, -C(O)O-(CH)-X-R, or -C(O)NH-(CH)-X-R； q is 1, 2, 3, 4, 5, or 6； X is -0-, -S-, -NH-, or -NHC(O)-； R is H or alkyl； R is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocyclic.
